ER+/ HER2 -ve Breast Cancer Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | AstraZeneca, BeiGene, CytomX, Olema Pharmaceuticals, Roche, Sanofi

February 12 16:22 2024
ER+/ HER2 -ve Breast Cancer Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | AstraZeneca, BeiGene, CytomX, Olema Pharmaceuticals, Roche, Sanofi
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 40+ key pharma and biotech companies are working on 50+ pipeline drugs in the ER+/ HER2 -ve Breast Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

ER+/ HER2 -ve Breast Cancer Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the ER+/ HER2 -ve Breast Cancer Market. 

The ER+/ HER2 -ve Breast Cancer Pipeline report embraces in-depth commercial, regulatory, and ER+/ HER2 -ve Breast Cancer clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging ER+/ HER2 -ve Breast Cancer drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

ER+/ HER2 -ve Breast Cancer Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for ER+/ HER2 -ve Breast Cancer treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different ER+/ HER2 -ve Breast Cancer therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major ER+/ HER2 -ve Breast Cancer companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the ER+/ HER2 -ve Breast Cancer drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the ER+/ HER2 -ve Breast Cancer therapeutic market.

ER+/ HER2 -ve Breast Cancer Therapeutics Landscape

Around 40+ major pharma and biotech companies are actively involved in the development of therapies targeting ER+/HER2-VE Breast Cancer. Among these, notable players such as AstraZeneca have advanced their drug candidates for ER+/HER2-VE Breast Cancer to the most advanced stage of clinical trials, namely Phase III. This underscores the significant dedication within the pharmaceutical industry to combat this subtype of breast cancer, offering promising prospects for potential treatments in the foreseeable future.

ER+/ HER2 -ve Breast Cancer Companies Actively Working in the Therapeutic Market Include:

  • AstraZeneca

  • BeiGene

  • CytomX Therapeutics

  • G1 Therapeutics

  • H3 Biomedicine

  • Jiangsu HengRui Medicine

  • Olema Pharmaceuticals

  • Roche

  • Sanofi

And Many Others

Emerging and Marketed ER+/ HER2 -ve Breast Cancer Drugs Covered in the Report Include:

  • AZD9833: Astrazeneca

  • BGB-290: BeiGene

And Many Others

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and ER+/ HER2 -ve Breast Cancer Companies Working in the Market:

https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight

Analysis of Emerging ER+/ HER2 -ve Breast Cancer Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

ER+/ HER2-VE Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion

  • Intradermal

  • Intramuscular

  • Intranasal

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Vaccines

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

Learn How the ER+/ HER2 -ve Breast Cancer Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market:

https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. ER+/ HER2 -ve Breast Cancer Treatment Patterns

4. ER+/ HER2 -ve Breast Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. ER+/ HER2 -ve Breast Cancer Late Stage Products (Phase-III)

7. ER+/ HER2 -ve Breast Cancer Mid-Stage Products (Phase-II)

8. ER+/ HER2 -ve Breast Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. ER+/ HER2 -ve Breast Cancer Discontinued Products

13. ER+/ HER2 -ve Breast Cancer Product Profiles

14. Major ER+/ HER2 -ve Breast Cancer Companies in the Market

15. Key Products in the ER+/ HER2 -ve Breast Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. ER+/ HER2 -ve Breast Cancer Unmet Needs

18. ER+/ HER2 -ve Breast Cancer Future Perspectives

19. ER+/ HER2 -ve Breast Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Other Trending Healthcare Reports By DelveInsight

Hypersomnia Market

“Hypersomnia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hypersomnia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hypersomnia market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology

  Categories: